A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3) (OPUS-3)
A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease and History of Recent Artificial Tear Use
Sponsor: Shire
A PHASE3 clinical study on Dry Eye Disease, this trial is completed. The trial is conducted by Shire and has accumulated 13 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Sep 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE3
-
May 2017 — Jul 2017 [monthly]
Completed PHASE3
-
Feb 2017 — May 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shire
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Artesia, United States , Birmingham, United States , Chandler, United States , Chesterfield, United States , Cleveland, United States , Cranberry Township, United States , Doylestown, United States , El Paso, United States , Hoffman Estates, United States , Houston, United States and 26 more locations